Lack of Impact by SCY‐078, a First‐in‐Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug‐Drug Interactions

SCY‐078, the first in a new class of β 1,3‐glucan synthesis inhibitors, is being developed as an oral and intravenous antifungal treatment for Candida and Aspergillus species fungal infections. In vitro, studies indicated SCY‐078 is an inhibitor of cytochrome P450 (CYP) 2C8 with markedly lower effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Wring, Stephen, Murphy, Gail, Atiee, George, Corr, Christy, Hyman, Michele, Willett, Michael, Angulo, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Drug Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175093/
https://www.ncbi.nlm.nih.gov/pubmed/29746713
http://dx.doi.org/10.1002/jcph.1146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175093/
https://www.ncbi.nlm.nih.gov/pubmed/29746713
http://dx.doi.org/10.1002/jcph.1146

Ejemplares similares